{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:30:44Z","timestamp":1785598244676,"version":"3.56.0"},"reference-count":30,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY035435"],"award-info":[{"award-number":["R01EY035435"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NEI","award":["P30EY025580"],"award-info":[{"award-number":["P30EY025580"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Patients with non-proliferative macular telangiectasia type 2 (MacTel) have ganglion cell layer (GCL) and nerve fibre layer (NFL) loss, but it is unclear whether the thinning is progressive. We quantified the change in retinal layer thickness over time in MacTel with and without diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective, multicentre, comparative case series, subjects with MacTel with at least two optical coherence tomographic (OCT) scans separated by &gt;9 months OCTs were segmented using the Iowa Reference Algorithms. Mean NFL and GCL thickness was computed across the total area of the early treatment diabetic retinopathy study grid and for the inner temporal region to determine the rate of thinning over time. Mixed effects models were fit to each layer and region to determine retinal thinning for each sublayer over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>115 patients with MacTel were included; 57 patients (50%) had diabetes and 21 (18%) had a history of carbonic anhydrase inhibitor (CAI) treatment. MacTel patients with and without diabetes had similar rates of thinning. In patients without diabetes and untreated with CAIs, the temporal parafoveal NFL thinned at a rate of \u22120.25\u00b10.09\u2009\u00b5m\/year (95% CI [\u22120.42 to \u20130.09]; p=0.003). The GCL in subfield 4 thinned faster in the eyes treated with CAI (\u22121.23\u00b10.21\u2009\u00b5m\/year; 95% CI [\u22121.64 to \u20130.82]) than in untreated eyes (\u22120.19\u00b10.16; 95% CI [\u22120.50, 0.11]; p&lt;0.001), an effect also seen for the inner nuclear layer. Progressive outer retinal thinning was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with MacTel sustain progressive inner retinal neurodegeneration similar to those with diabetes without diabetic retinopathy. Further research is needed to understand the consequences of retinal thinning in MacTel.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2023-325115","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T17:20:32Z","timestamp":1726593632000},"page":"401-407","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2"],"prefix":"10.1136","volume":"109","author":[{"given":"Alec L","family":"Amram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0161-9625","authenticated-orcid":false,"given":"S Scott","family":"Whitmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Clavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance J","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M","family":"Rusakevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Folk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Culver","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-0037","authenticated-orcid":false,"given":"Michael","family":"Abramoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3778-9362","authenticated-orcid":false,"given":"Elliott H","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2025040422452237000_109.3.401.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(93)31447-8"},{"key":"2025040422452237000_109.3.401.2","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1167\/iovs.15-16915","article-title":"Progression of Vision Loss in Macular Telangiectasia Type 2","volume":"56","author":"Heeren","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025040422452237000_109.3.401.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2012.11.002"},{"key":"2025040422452237000_109.3.401.4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","article-title":"Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial","volume":"126","author":"Chew","year":"2019","journal-title":"Ophthalmology"},{"key":"2025040422452237000_109.3.401.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.11.019"},{"key":"2025040422452237000_109.3.401.6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31824690a8","article-title":"Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial","volume":"32","author":"Toy","year":"2012","journal-title":"Retina"},{"key":"2025040422452237000_109.3.401.7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/IAE.0000000000000093","article-title":"Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors","volume":"34","author":"Chen","year":"2014","journal-title":"Retina"},{"key":"2025040422452237000_109.3.401.8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ng.3799","article-title":"Genome-wide analyses identify common variants associated with macular telangiectasia type 2","volume":"49","author":"Scerri","year":"2017","journal-title":"Nat Genet"},{"key":"2025040422452237000_109.3.401.9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/jamaophthalmol.2018.3283","article-title":"Genetic Penetrance of Macular Telangiectasia Type 2","volume":"136","author":"Ronquillo","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2025040422452237000_109.3.401.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815111"},{"key":"2025040422452237000_109.3.401.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.04.013"},{"key":"2025040422452237000_109.3.401.12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamaophthalmol.2014.3950","article-title":"Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography","volume":"133","author":"Spaide","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2025040422452237000_109.3.401.13","doi-asserted-by":"publisher","DOI":"10.3109\/09286580903450361"},{"key":"2025040422452237000_109.3.401.14","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1357"},{"key":"2025040422452237000_109.3.401.15","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15672"},{"key":"2025040422452237000_109.3.401.16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaophthalmol.2019.2536","article-title":"Diabetic Retinal Neurodegeneration-Should We Redefine Retinopathy From Diabetes?","volume":"137","author":"Sohn","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"2025040422452237000_109.3.401.17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10311"},{"key":"2025040422452237000_109.3.401.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522014113"},{"key":"2025040422452237000_109.3.401.19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1167\/iovs.14-15885","article-title":"Relationships of retinal structure and humphrey 24-2 visual field thresholds in patients with glaucoma","volume":"56","author":"Bogunovi\u0107","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025040422452237000_109.3.401.20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ophtha.2020.10.008","article-title":"Updating the Staging System for Diabetic Retinal Disease","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"2025040422452237000_109.3.401.21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1167\/iovs.17-21873","article-title":"Approach for a Clinically Useful Comprehensive Classification of Vascular and Neural Aspects of Diabetic Retinal Disease","volume":"59","author":"Abramoff","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025040422452237000_109.3.401.22","doi-asserted-by":"publisher","DOI":"10.1109\/RBME.2010.2084567"},{"key":"2025040422452237000_109.3.401.23","doi-asserted-by":"publisher","DOI":"10.1109\/TMI.2009.2016958"},{"key":"2025040422452237000_109.3.401.24","doi-asserted-by":"crossref","DOI":"10.1002\/jbio.201960187","article-title":"Comparison of the Iowa Reference Algorithm to the Heidelberg Spectralis optical coherence tomography segmentation algorithm","volume":"13","author":"Sun","year":"2020","journal-title":"J Biophotonics"},{"key":"2025040422452237000_109.3.401.25","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10420"},{"key":"2025040422452237000_109.3.401.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.001"},{"key":"2025040422452237000_109.3.401.27","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31822091b0"},{"key":"2025040422452237000_109.3.401.28","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.oret.2021.01.002","article-title":"Prevalence and Severity of Diabetic Retinopathy in Patients with Macular Telangiectasia Type 2","volume":"5","author":"van Romunde","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"2025040422452237000_109.3.401.29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamaophthalmol.2015.1796","article-title":"Macular Telangiectasia Type 2 Without Clinically Detectable Vasculopathy","volume":"133","author":"Gillies","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2025040422452237000_109.3.401.30","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/IAE.0000000000001697","article-title":"CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6-The MacTel Research Group","volume":"38 Suppl 1","author":"Peto","year":"2018","journal-title":"Retina (Philadelphia, Pa)"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-325115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:29:50Z","timestamp":1743845390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-325115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,24]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bjo-2023-325115"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-325115","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}